Resting Cardiac Efficiency Affects Survival Following Transcatheter Aortic Valve Replacement.


Journal

Cardiovascular revascularization medicine : including molecular interventions
ISSN: 1878-0938
Titre abrégé: Cardiovasc Revasc Med
Pays: United States
ID NLM: 101238551

Informations de publication

Date de publication:
11 2020
Historique:
received: 24 12 2019
revised: 15 03 2020
accepted: 09 04 2020
pubmed: 23 4 2020
medline: 16 7 2021
entrez: 23 4 2020
Statut: ppublish

Résumé

Cardiac power to left ventricular mass (LVM) ratio, also termed cardiac efficiency (CE), reflects the rate of cardiac work delivered to the potential energy stored in LVM. We sought to assess the association between baseline resting CE and survival post transcatheter aortic valve replacement (TAVR). We retrospectively extracted data of patients who received TAVR in the Mayo Clinic Foundation with follow up data available at 1 year. Cardiac output was measured using Doppler echocardiography at baseline. CE was calculated using the formula, (cardiac output × mean arterial blood pressure)/(451 × LVM × 100) W/100 g. Survival score analysis was performed to identify cut off value for CE to identify the maximum difference in mortality in the study cohort. Patients were subsequently divided into 2 groups CE < 0.38 W/100 g and CE ≥ 0.38 W/100 g. Survival was determined using Kaplan-Meier method. We included 954 patients in the final analysis. CE in group1 vs group 2 was 0.31 ± 0.05 W/100 g vs 0.59 ± 0.18 W/100 g. Patients in group1 were more likely to be male, had a higher prevalence of atrial fibrillation, prior myocardial infarction, mitral and tricuspid regurgitation. They also had a higher STS risk score, NYHA functional class, and lower aortic valve area. The remainder of the baseline characteristics was similar in both groups. A lower CE was associated with higher 1-year mortality following TAVR based on multivariate analysis. (Group1: 22.18% vs Group 2: 9.89%, p < .0001). In our cohort, a low baseline CE (<0.38 W/100 g) conferred higher mortality risk following TAVR.

Identifiants

pubmed: 32317228
pii: S1553-8389(20)30219-0
doi: 10.1016/j.carrev.2020.04.015
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1327-1333

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors report no financial relationships or conflicts of interest regarding the content herein.

Auteurs

Pradyumna Agasthi (P)

Department of Cardiovascular Diseases, Mayo Clinic Arizona, 5777 E Mayo Blvd, Phoenix, AZ, United States of America. Electronic address: agasthi.pradyumna@mayo.edu.

Sai Harika Pujari (SH)

Department of Cardiovascular Diseases, Mayo Clinic Arizona, 5777 E Mayo Blvd, Phoenix, AZ, United States of America.

Farouk Mookadam (F)

Department of Cardiovascular Diseases, Mayo Clinic Arizona, 5777 E Mayo Blvd, Phoenix, AZ, United States of America.

Nithin R Venepally (NR)

Department of Cardiovascular Diseases, Mayo Clinic Arizona, 5777 E Mayo Blvd, Phoenix, AZ, United States of America.

Hasan Ashraf (H)

Department of Cardiovascular Diseases, Mayo Clinic Arizona, 5777 E Mayo Blvd, Phoenix, AZ, United States of America.

Floyd David Fortuin (FD)

Department of Cardiovascular Diseases, Mayo Clinic Arizona, 5777 E Mayo Blvd, Phoenix, AZ, United States of America.

Panwen Wang (P)

Department of Health Sciences Research, Mayo Clinic Arizona, 5777 E Mayo Blvd, Phoenix, AZ, United States of America.

Mohamed Allam (M)

Department of Cardiovascular Diseases, Mayo Clinic Arizona, 5777 E Mayo Blvd, Phoenix, AZ, United States of America.

John Sweeney (J)

Department of Cardiovascular Diseases, Mayo Clinic Arizona, 5777 E Mayo Blvd, Phoenix, AZ, United States of America.

Mackram Eleid (M)

Department of Cardiovascular Diseases, Mayo Clinic Rochester, Rochester, MN, United States of America.

Peter Pollak (P)

Department of Cardiovascular Diseases, Mayo Clinic Florida, 4500 San Pablo Rd S, Jacksonville, FL, United States of America.

Kevin L Greason (KL)

Department of Cardiovascular Surgery, Mayo Clinic Rochester, 200 1st St SW, Rochester, MN, United States of America.

Nirat Beohar (N)

Columbia University Division of Cardiology, Mount Sinai Medical Center, 4300 Alton Rd, Miami Beach, FL, United States of America.

Reza Arsanjani (R)

Department of Cardiovascular Diseases, Mayo Clinic Arizona, 5777 E Mayo Blvd, Phoenix, AZ, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH